LUPIN:NSE-Lupin Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 628.30

Change

0.00 (0.00)%

Market Cap

INR 283.50B

Volume

0.39M

Avg Analyst Target

INR 758.00 (+20.64%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


LUPIN Stock Forecast & Price:
Based on the Lupin Limited stock forecasts from 5 analysts, the average analyst target price for Lupin Limited is INR 758.00 over the next 12 months. Lupin Limited’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Lupin Limited is Slightly Bearish, which is based on 5 positive signals and 9 negative signals. At the last closing, Lupin Limited’s stock price was INR 628.30. Lupin Limited’s stock price has changed by -0.27% over the past week, +2.81% over the past month and -45.86% over the last year.

About Lupin Limited (LUPIN:NSE)

Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, active pharmaceutical ingredients (APIs), and specialty products in India, the United States, Japan, and internationally. It offers ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-04 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+0.15 (+0.02%)

INR1,994.80B 61.13 27.65
DIVISLAB:NSE Divi's Laboratories Limited

+2.00 (+0.05%)

INR958.40B 32.37 23.30
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-31.45 (-0.72%)

INR714.85B 30.40 15.87
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-12.80 (-0.44%)

INR493.58B 63.50 24.32
PEL:NSE Piramal Enterprises Limited

+7.60 (+0.45%)

INR400.11B 20.85 11.08
ALKEM:NSE Alkem Laboratories Limited

+20.20 (+0.67%)

INR358.31B 21.77 16.10
AUROPHARMA:NSE Aurobindo Pharma Limited

+6.80 (+1.30%)

INR304.98B 11.52 6.32
LAURUSLABS:NSE Laurus Labs Limited

+4.55 (+0.98%)

INR248.55B 30.06 19.05
IPCALAB:NSE IPCA Laboratories Limited

+5.60 (+0.61%)

INR231.10B 26.14 16.39
AJANTPHARM:NSE Ajanta Pharma Limited

-24.85 (-1.97%)

INR159.98B 22.20 14.90

ETFs Containing LUPIN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -33.92% 19% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.92% 21% F 17% F
Trailing 12 Months  
Capital Gain -45.74% 20% F 7% F
Dividend Return 0.56% 56% F 35% F
Total Return -45.18% 23% F 7% F
Trailing 5 Years  
Capital Gain -42.04% 12% F 28% F
Dividend Return 2.77% 50% F 40% F
Total Return -39.27% 14% F 28% F
Average Annual (5 Year Horizon)  
Capital Gain 1.95% 9% F 26% F
Dividend Return 0.65% 65% D 48% F
Total Return 2.60% 11% F 26% F
Risk Return Profile  
Volatility (Standard Deviation) 24.97% 92% A- 90% A-
Risk Adjusted Return 10.42% 14% F 29% F
Market Capitalization 283.50B 90% A- 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.10 43% F 40% F
Price/Book Ratio 2.37 58% F 42% F
Price / Cash Flow Ratio 77.18 11% F 8% F
EV/EBITDA 71.38 3% F 3% F
Management Effectiveness  
Return on Equity -11.58% 9% F 10% F
Return on Invested Capital 1.83% 18% F 30% F
Return on Assets 3.52% 33% F 47% F
Debt to Equity Ratio 1.17% 75% C 78% C+
Technical Ratios  
Dividend Yield 1.03% 56% F 52% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.67 54% F 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector